A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model

International Immunopharmacology

Volumn 10, Issue 9, 2010, Pages 1055-1061

  Langroudi, Ladan ^a   Hassan, Zuhir Muhammad ^a   Ebtekar, Massoumeh ^a   Mahdavi, Mehdi ^a   Pakravan, Nafise ^a   Noori, Shokoofe ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Artemisinin; Breast cancer; Cyclophosphamide; Regulatory T cells

Indexed keywords

ARTEMISIN; BROXURIDINE; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; FEMALE; IMMUNOMODULATION; INTERFERON PRODUCTION; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ARTEMISININS; CARCINOMA, DUCTAL, BREAST; CYCLOPHOSPHAMIDE; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-4; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; SPLEEN; T-LYMPHOCYTES, REGULATORY;

EID: 77955982488     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.06.005     Document Type: Article

References (60)

1. SEER cancer statistics review. National Cancer Institute 2008, M. Krapcho, M.J.R.L. Horner, N. Neyman, R. Aminou, N. Howlader, E.J. Feuer, S.F. Altekruse, L. Huang, A. Mariotto, D.R. Lewis, B.A. Miller, M.P. Eisner, B.K. Edwards, D.G. Stinchcomb (Eds.).
2. Carol DeSantis M., Rebecca Siegel M., Ahmedin Jemal P. Breast cancer facts and figures. Amer Can Soct 2008, 2007- 2008.
3. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Sci 1985, 228(4703):1049-1055.
4. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Intl J Parasit 2002, 32(13):1655-1660.
5. Meshnick S.R., Taylor T.E., Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microb Mol Biol Rev 1996, 60(2):301.
6. Yeka A., Banek K., Bakyaita N., Staedke S.G., Kamya M.R., Talisuna A., et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med 2005, 2(7):654.
7. Ratcliff A., Siswantoro H., Kenangalem E., Maristela R., Laihad F., Wuwung R.M., et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007, 369(9563):757-765. 2007/3/9/.
8. Kumura N., Furukawa H., Onyango A.N., Izumi M., Nakajima S., Ito H., et al. Different behavior of artemisinin and tetraoxane in the oxidative degradation of phospholipid. Chem Phys Lipids 2009, 160(2):114-120.
9. Konkimalla V.B., Blunder M., Thedinga E., Korn B., Bauer R., Efferth T. Artemisinin derivatives induce generation of nitric oxide and reactive oxygen species in cell lines of hematopoietic origin. Poster abstracts Nitric Oxide 2007, 17:21-22.
10. Qian Z.M., Li H., Sun H., Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002, 54:561-587.
11. Gomme P.T., McCann K.B., Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005, 10:267-273.
12. Lai H., Singh N.P. Oral artemisinin prevents and delays the development of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett 2006, 231(1):43-48.
13. Lu Y.-Y., Chen T.-S., Qu J.-L., Pan W.-L., Sun L., Wei X.-B. Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. J Biomed Sci 2009, 16:16.
14. Nakase I., Gallis B., Takatani-Nakase T., Oh S., Lacoste E., Singh N.P., et al. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett 2009, 274(2):290-298.
15. Nakase I., Lai H., Singh N.P., Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Intl J Pharmaceutics 2008, 354(1-2):28-33.
16. Oh S., Kim B.J., Singh N.P., Lai H., Sasaki T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 2009, 274(1):33-39.
17. Wang J., Zhang B.C., Guo Y., Li G.H., Xie Q.C., Zhu B., et al. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology 2008, 82(2):148-155.
18. Youns M., Efferth T., Reichling J., Fellenberg K., Bauer A., Hoheisel J.D. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem Pharmac 2009, 78(3):273-283.
19. Polyak Kornelia, Haviv Izhak, Campbell Ian G. Co-evolution of tumor cells and their microenvironment. cell press 2008, 25(1):9.
20. Rüegg G.L.C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008, 130:1091-1103.
21. Rivoltini L., Carrabba M., Huber V., Castelli C., Novellino L., Dalerba P., et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002, 188:97-113.
22. Hanna J., Mandelboim O. When killers become helpers. Trends Immunol 2007, 28(5):201-206.
23. Ferrone S.M., Whiteside T.L. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007, 16:755-774.
24. Ghiringhelli F., Ménard C., Terme M., Flament C., Taieb J., Chaput N., et al. Tumor cells convert immature myeloid dendritic cells into TGF-β secreting cells inducing CD4 CD25 regulatory T cell proliferation. J Exp Med 2005, 202(7):919-929.
25. Wolfers J., Lozier A., Raposo G., Regnault A., Théry C., Masurier C., et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001, 7(3):297-303.
26. Kim Ryungsa, Tanabe K., Manabu Emi, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006, 66(11):5527-5536. 2006.
27. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-949.
28. Shevach E.M. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004, 10(9):900-901.
29. Valzasina B., Piconese S., Guiducci C., Colombo M.P. Tumor-induced expansion of regulatory T cells by conversion of CD4+ CD25-lymphocytes is thymus and proliferation independent. AACR 2006, 4488-4495.
30. Motoyoshi Y., Kaminoda K., Saitoh O., Hamasaki K., Nakao K., Ishii N., et al. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006, 16(1):141-146.
31. Taieb J., Chaput N., Schartz N., Roux S., Novault S., Menard C., et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immun 2006, 176(5):2722-2729.
32. Zhang Z., Zhang M., Ravetch J.V., Goldman C.K., Waldmann T.A. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. AACR 2003, 6453-6457.
33. Zhang M., Zhang Z., Garmestani K., Schultz J., Axworthy D.B., Goldman C.K., et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci 2003, 100(4):1891-1895.
34. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Sci 1996, 271(5256):1734.
35. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci 2003, 100(14):8372-8377.
36. Fleming R. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997, 17(5):146-154.
37. Philip W., Fischer D.S. Cancer chemotherapeutic agents. Encyclopedia of Toxicology 2005, 384-401. Elsevier, New York.
38. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001, 358(9292):1511-1513.
39. Ehrke M. Immunomodulation in cancer therapeutics. Intl Immunopharmacol 2003, 3(8):1105-1119.
40. V.Radojcic , K. Bezak , M. Skarica , M. Pletneva , K. Yoshimura , R. Schulick , et al. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Imm Immtherap. 59(1): 137-48 January 2010.
41. Schiavoni G., Mattei F., Di Pucchio T., Santini S., Bracci L., Belardelli F., et al. Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000, 6:2024.
42. Bracci L., Moschella F., Sestili P., La Sorsa V., Valentini M., Canini I., et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Can Res 2007, 13(2):644-653. January 15, 2007.
43. Matar P., Rozados V.R., Gervasoni S.I., Scharovsky O.G. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Intl Immunopharmacology 2001, 1(2):307-319.
44. Ebtekar M., Hassan Z.M. Effect of immunomodulators pyrimethamine and cimetidine on immunosuppression induced by sulfur mustard in mice. Intl j immunopharmacology 1993, 15(4):533-541.
45. Hassan Z.M., Yaraee R., Zare N., Ghazanfari T., Sarraf Nejad A.H., Nazori B. Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity. Intl. Immunopharmacology 2003, 3(10-11):1483-1489.
46. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998, 58(21):4947-4956.
47. Ke O.Y., Krug E.C., Marr J.J., Berens R.L. Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimicrob Agents Chemother 1990, 34(10):1961-1965.
48. Merali S., Meshnick S.R. Susceptibility of Pneumocystis carinii to artemisinin in vitro. Antimicrob Agents Chemother 1991, 35(6):1225-1227.
49. Efferth T., Romero Marta R., Wolf Dana G., Stamminger T., Marin Jose Â.J.Â.G., Marschall M. The antiviral activities of artemisinin and artesunate. Clinical Infectious Diseases 2008, 47(6):804-811.
50. He Z, Chen L, You J, Qin L, Chen X. In vitro interactions between antiretroviral protease inhibitors and artemisinin endoperoxides against Plasmodium falciparum. International Journal of Antimicrobial Agents. In Press, Corrected Proof.
51. Kaptein S., Efferth T., Leis M., Rechter S., Auerochs S., Kalmer M., et al. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antivir Res 2006, 69(2):60-69.
52. Milbradt J., Auerochs S., Korn K., Marschall M. Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate. J Clin Virol 2009, 46(1):24-28.
53. Lai H., Singh N. Selective cancer cell cytoxicity from exposure in dihydroartemisinin and holotransferrin. Cancer Lett 1995, 91:41-46.
54. Sundar S.N., Marconett C.N., Doan V.B., Willoughby J.A., Firestone G.L. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 2008, 29(12):2252-2258.
55. Chen H., Sun B., Pan S.H., Jiang H.C., Sun X.Y. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009, 20(2):131-140.
56. Berger T.G., Dieckmann D., Efferth T., Schultz E.S., Funk J.O., Baur A., et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep 2005, 14(6):1599-1603.
57. Hayden B.J., Askenase P.W., Gershon R.K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 1975, 141(3):697-702. March 1, 1975.
58. Noori S., Taghikhani M., Al-lameh A., Hassan Z.M., Mostafaei A. Tehranolide could shift the immune response towards Th1 and modulate the intra-tumor infiltrated T regulatory cells. Iran J Immunol 2009, 6(4):216-224.
59. Willoughby J., Sundar S., Cheung M., Tin A., Modiano J., Firestone G. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009, 284(4):2203.
60. Beyer M., Schultze J.L. Regulatory T cells: major players in the tumor microenvironment. Cur Pharmaceutical Design 2009 Jun, 15(16):1879-1892.